GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (STU:4QG) » Definitions » Valuation Rank

PCI Biotech Holding ASA (STU:4QG) Valuation Rank


View and export this data going back to 2015. Start your Free Trial

What is PCI Biotech Holding ASA Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

PCI Biotech Holding ASA Valuation Rank Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

PCI Biotech Holding ASA (STU:4QG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (STU:4QG) » Definitions » Valuation Rank
Comparable Companies
OSL:ABTEC OSL:SOFTX OSL:CRNA OSL:ABS OSL:LYTIX OSL:TRMED OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB
Traded in Other Exchanges
PCIB:Norway 4QG:Germany
Address
Ullernchausseen 64, Oslo, NOR, N-0379
Website
https://www.pcibiotech.com
PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.